Identification and characterization of a novel CXC chemokine in xenograft tumor induced by mas-overexpressing cells
Publication in refereed journal

Times Cited
Web of Science4WOS source URL (as at 25/09/2020) Click here for the latest count
Altmetrics Information

Other information
AbstractOverexpressions of G protein-coupled receptor (GPCR) with elevated downstream signaling events have been reported in various tumors. However, the cellular mechanism that GPCR overexpression leads to tumor formation is largely unknown. The orphan GPCR mas was originally isolated from a human epidermoid carcinoma. In vivo studies of mas-overexpressing cells suggested that xenograft tumor formation was positively correlated with the levels of mas expression. Histochemical analysis indicated that xenograft tumor consisted of mas-transfected and stromal cells. Biochemical analyses revealed that cells overexpressing mas exhibited significantly increased anchorage-independent growth, whereas there was no significant difference in cell proliferation in comparison with empty vector-transfected control cells. Expression profiling using mRNA differential display and Northern analysis indicated an elevated expression of GRO and a novel CXC chemokines, tumor-induced factor (TIF), in mas-transfected cells and xenograft tumor. Bacterially expressed recombinant TIF was found to act as a neutrophil chemoattractant in a chemotactic assay. These results suggest that mas overexpression enables anchorage-independent growth of transformed cells, and interplays of secreted chemokines with stromal cells modulate xenograft tumor formation. Importantly, a novel CXC chemokine, TIF, was identified in the xenograft tumor tissues. (C) 2009 UICC
All Author(s) ListLin WZ, Li ZF, Tsang SY, Lung LKW, Wang DK, Chan WY, Zhu YK, Lee SST, Cheung WT
Journal nameInternational Journal of Cancer
Volume Number125
Issue Number6
Pages1316 - 1327
LanguagesEnglish-United Kingdom
KeywordsCXC chemokines; GRO; mas; orphan GPCR; tumor-induced factor
Web of Science Subject CategoriesOncology; ONCOLOGY

Last updated on 2020-25-09 at 11:26